Drug resistance mechanisms and drug susceptibility testing for tuberculosis
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is the deadliest infectious
disease and the associated global threat has worsened with the emergence of drug …
disease and the associated global threat has worsened with the emergence of drug …
[HTML][HTML] Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide
Inclusion of pyrazinamide (PZA) in the tuberculosis (TB) drug regimen during the 1970s
enabled a reduction in treatment duration from 12 to 6 months. PZA has this remarkable …
enabled a reduction in treatment duration from 12 to 6 months. PZA has this remarkable …
[HTML][HTML] Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide
To be effective, chemotherapy against tuberculosis (TB) must kill the intracellular population
of the pathogen, Mycobacterium tuberculosis. However, how host cell microenvironments …
of the pathogen, Mycobacterium tuberculosis. However, how host cell microenvironments …
Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
SM Irwin, B Prideaux, ER Lyon… - ACS infectious …, 2016 - ACS Publications
BALB/c and Swiss mice are routinely used to validate the effectiveness of tuberculosis drug
regimens, although these mouse strains fail to develop human-like pulmonary granulomas …
regimens, although these mouse strains fail to develop human-like pulmonary granulomas …
[HTML][HTML] A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide
AN Yadon, K Maharaj, JH Adamson, YP Lai… - Nature …, 2017 - nature.com
Tuberculosis chemotherapy is dependent on the use of the antibiotic pyrazinamide, which is
being threatened by emerging drug resistance. Resistance is mediated through mutations in …
being threatened by emerging drug resistance. Resistance is mediated through mutations in …
[HTML][HTML] Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy
RC Lavin, S Tan - PLoS Pathogens, 2022 - journals.plos.org
A hallmark of Mycobacterium tuberculosis (Mtb) infection is the marked heterogeneity that
exists, spanning lesion type differences to microenvironment changes as infection …
exists, spanning lesion type differences to microenvironment changes as infection …
Pyrazinamide resistance is caused by two distinct mechanisms: prevention of coenzyme A depletion and loss of virulence factor synthesis
Pyrazinamide (PZA) is a critical component of first-and second-line treatments of
tuberculosis (TB), yet its mechanism of action largely remains an enigma. We carried out a …
tuberculosis (TB), yet its mechanism of action largely remains an enigma. We carried out a …
[HTML][HTML] The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis. It is
active against the persistent, non-replicating mycobacteria responsible for the protracted …
active against the persistent, non-replicating mycobacteria responsible for the protracted …
The bewildering antitubercular action of pyrazinamide
Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …
[HTML][HTML] Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
EJ Hasenoehrl, TJ Wiggins, M Berney - Frontiers in cellular and …, 2021 - frontiersin.org
Development of novel anti-tuberculosis combination regimens that increase efficacy and
reduce treatment timelines will improve patient compliance, limit side-effects, reduce costs …
reduce treatment timelines will improve patient compliance, limit side-effects, reduce costs …